» Articles » PMID: 34906181

Transmission of Synovial Sarcoma from a Single Multi-organ Donor to Three Transplant Recipients: Case Report

Overview
Journal Diagn Pathol
Publisher Biomed Central
Specialty Pathology
Date 2021 Dec 15
PMID 34906181
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Transmission of malignancy is a notable problem that cannot always be absolutely predicted at the time of transplantation. In particular, donor-derived transmission of synovial sarcoma in solid-organ transplantation is a rare but catastrophic event.

Case Presentation: We are the first to report three cases of synovial sarcoma transmitted from a single multi-organ donor in China. The donor died of respiratory failure caused by an intrathoracic tumor, which was diagnosed as benign at the time of donation. All three recipients developed synovial sarcoma 3-13 months after transplantation; all three cases were confirmed to be donor transmitted. The liver transplant recipient died of tumor metastasis after partial-allograft hepatectomy. The two renal-transplant recipients survived after comprehensive therapy, including allograft nephrectomy, withdrawal of immunosuppressants and targeted therapy with anlotinib.

Conclusions: This report highlights the importance of detailed donor assessment, close follow-up and timely treatment of unexpected donor-transmitted malignancy. Although pathology is the most important evidence for the exclusion of donors for malignant potential, it should be combined with tumor type, tumor size and speed of growth. Organs from donors with malignant potential should be discarded. Allograft nephrectomy should be considered after confirmation of renal-allograft synovial sarcoma. Anlotinib for synovial sarcoma seems to be effective and well tolerated during long-term follow-up.

Citing Articles

Case report: A successful clinical experience of transplantation of liver and kidney from a donor with myelodysplastic syndromes.

Huang K, Zhang Q, Wu S, Zhou L, Liang W, Hu X Front Immunol. 2024; 15:1360955.

PMID: 38633259 PMC: 11021682. DOI: 10.3389/fimmu.2024.1360955.


Immunotherapy and Antivascular Targeted Therapy in Patients' Treatment with Concurrent Malignant Tumors after Organ Transplantation: Opportunity or Challenge.

Shen B, Guo Z, Huang P, Tan M, Zhang X, Lin S J Immunol Res. 2022; 2022:6440419.

PMID: 35692497 PMC: 9184147. DOI: 10.1155/2022/6440419.

References
1.
Eccher A, Girolami I, Motter J, Marletta S, Gambaro G, Momo R . Donor-transmitted cancer in kidney transplant recipients: a systematic review. J Nephrol. 2020; 33(6):1321-1332. PMC: 7701067. DOI: 10.1007/s40620-020-00775-4. View

2.
Matser Y, Terpstra M, Nadalin S, Nossent G, de Boer J, van Bemmel B . Transmission of breast cancer by a single multiorgan donor to 4 transplant recipients. Am J Transplant. 2018; 18(7):1810-1814. DOI: 10.1111/ajt.14766. View

3.
Demicco E, Harms P, Patel R, Smith S, Ingram D, Torres K . Extensive survey of STAT6 expression in a large series of mesenchymal tumors. Am J Clin Pathol. 2015; 143(5):672-82. PMC: 4505928. DOI: 10.1309/AJCPN25NJTOUNPNF. View

4.
Green M, Covington S, Taranto S, Wolfe C, Bell W, Biggins S . Donor-derived transmission events in 2013: a report of the Organ Procurement Transplant Network Ad Hoc Disease Transmission Advisory Committee. Transplantation. 2015; 99(2):282-7. DOI: 10.1097/TP.0000000000000584. View

5.
Xiao D, Craig J, Chapman J, Dominguez-Gil B, Tong A, Wong G . Donor cancer transmission in kidney transplantation: a systematic review. Am J Transplant. 2013; 13(10):2645-52. DOI: 10.1111/ajt.12430. View